81 related articles for article (PubMed ID: 23602523)
1. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors.
El-Zoghbi MS; Bass AK; A Abuo-Rahma GE; Mohamed MF; Badr M; Al-Ghulikah HA; Abdelhafez EM
Future Med Chem; 2024 Apr; 16(7):601-622. PubMed ID: 38436113
[No Abstract] [Full Text] [Related]
3. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).
Sinatra L; Bandolik JJ; Roatsch M; Sönnichsen M; Schoeder CT; Hamacher A; Schöler A; Borkhardt A; Meiler J; Bhatia S; Kassack MU; Hansen FK
Angew Chem Int Ed Engl; 2020 Dec; 59(50):22494-22499. PubMed ID: 32780485
[TBL] [Abstract][Full Text] [Related]
4. First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.
Karaj E; Sindi SH; Kuganesan N; Koranne RA; Knoff JR; James AW; Fu Y; Kotsull LN; Pflum MK; Shah Z; Taylor WR; Tillekeratne LMV
J Med Chem; 2022 Nov; 65(21):14764-14791. PubMed ID: 36306372
[TBL] [Abstract][Full Text] [Related]
5. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.
Raji I; Yadudu F; Janeira E; Fathi S; Szymczak L; Kornacki JR; Komatsu K; Li JD; Mrksich M; Oyelere AK
Bioorg Med Chem; 2017 Feb; 25(3):1202-1218. PubMed ID: 28057407
[TBL] [Abstract][Full Text] [Related]
6. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
Patel HK; Siklos MI; Abdelkarim H; Mendonca EL; Vaidya A; Petukhov PA; Thatcher GR
ChemMedChem; 2014 Mar; 9(3):602-13. PubMed ID: 23956109
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Raji I; Ahluwalia K; Oyelere AK
Bioorg Med Chem Lett; 2017 Feb; 27(4):744-749. PubMed ID: 28131715
[TBL] [Abstract][Full Text] [Related]
8. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.
Hanigan TW; Aboukhatwa SM; Taha TY; Frasor J; Petukhov PA
Cell Chem Biol; 2017 Nov; 24(11):1356-1367.e8. PubMed ID: 28943357
[TBL] [Abstract][Full Text] [Related]
9. Dual-acting histone deacetylase-topoisomerase I inhibitors.
Guerrant W; Patil V; Canzoneri JC; Yao LP; Hood R; Oyelere AK
Bioorg Med Chem Lett; 2013 Jun; 23(11):3283-7. PubMed ID: 23622981
[TBL] [Abstract][Full Text] [Related]
10. Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout.
Steimbach RR; Herbst-Gervasoni CJ; Lechner S; Stewart TM; Klinke G; Ridinger J; Géraldy MNE; Tihanyi G; Foley JR; Uhrig U; Kuster B; Poschet G; Casero RA; Médard G; Oehme I; Christianson DW; Gunkel N; Miller AK
J Am Chem Soc; 2022 Oct; 144(41):18861-18875. PubMed ID: 36200994
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs.
Guerra-Bubb JM; Bowers AA; Smith WB; Paranal R; Estiu G; Wiest O; Bradner JE; Williams RM
Bioorg Med Chem Lett; 2013 Nov; 23(21):6025-8. PubMed ID: 24035339
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of phenoxybenzamine and its inhibition of histone deacetylases.
Inchiosa MA
PLoS One; 2018; 13(6):e0198514. PubMed ID: 29897996
[TBL] [Abstract][Full Text] [Related]
13. A "Double-Locked" and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy.
Luo J; Guan Z; Gao W; Wang C; Xu Z; Meng C; Liu Y; Zhang Y; Guo Q; Ling Y
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056740
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
[TBL] [Abstract][Full Text] [Related]
15. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.
Nie J; Wu H; Luan Y; Wu J
Mini Rev Med Chem; 2024; 24(5):480-490. PubMed ID: 37461341
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells.
Ovejero-Sánchez M; Asensio-Juárez G; González M; Puebla P; Vicente-Manzanares M; Pélaez R; González-Sarmiento R; Herrero AB
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361809
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Predictive Biomarkers in Gliomas.
Śledzińska P; Bebyn MG; Furtak J; Kowalewski J; Lewandowska MA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638714
[TBL] [Abstract][Full Text] [Related]
18. Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Smalley JP; Cowley SM; Hodgkinson JT
Molecules; 2020 Sep; 25(19):. PubMed ID: 32987782
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent.
Xu Q; Liu C; Zang J; Gao S; Chou CJ; Zhang Y
Front Cell Dev Biol; 2020; 8():454. PubMed ID: 32760715
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
